终末期肝病周围循环功能障碍发生原因和机制与临床关系

摘要/Abstract

摘要： 终末期肝病患者周围循环功能障碍(peripheral circulation dysfunction,PCD)发病原因和发病机制复杂,相关学说存在较多争议和挑战性问题。本文就终末期肝病患者PCD发病原因、发病机制与相关并发症诊断和治疗理论依据的临床研究进展作一综述。

关键词: 终末期肝病, 周围循环功能障碍, 肝硬化, 多器官损伤

郑文凯, 刘建军, 刘研, 王江红, 任燕军. 终末期肝病周围循环功能障碍发生原因和机制与临床关系[J]. 肝脏, 2022, 27(5): 606-609.

[1] Schrler RW,Arroyo V,Bernardl M,et al.Peripheral arterial vasodilation hypothesis: Aproposal for the initiation of renal sodium and water retention in cirrhosis.Hepatology,1988,8(5):1151-1157.
[2] Gln SP,Sol E,Angeli P,et al.Hepatorenal syndrome.Nat Rev Dis Primers,2018,4(1):23.
[3] Kazory A,Ronco C. Hepatorenal syndrome or hepatocardiorenal syndrome: Revisiting basic concepts in view of emerging data.Cardiorenal Med,2019,9(1):1-7.
[4] Angeli P, Garcia-Tsao G,Mitra K,et al. News in pathophysiology,definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites(ICA) consensus document.J Hepatol,2019,71(4):811-822.
[5] 刘建军,牛蓓.对2017年《肝硬化腹水及相关并发症的诊疗指南》的解读与商榷.新医学杂志,2018,49(1):1-5.
[6] European Association for the Study of the Liver. EASL Clinical practice Guidelines for the management of patients with decompensated cirrhosis.J Hepatol,2018,69(2):406-460.
[7] Fuhrmann V,Krowka M. Hepatopulmonary syndrome.J Hepatol,2018,69(3):744-745.
[8] Davenport A,Shelkh MF,Lamb E,et al. Acute Kidney injury in acute on chronic liver failure: Where Does hepatorenal syndrome fit?.Kidney Int,2017,92(5):1058-1070.
[9] Meola M,Nalesso F,Petruccl I,et al. Clinical scenarios in acute kidney injury: Hepatorenal syndrome.Contrib Nephrol,2016,188:33-38.
[10] 李妍,陆伦根.重视肝肾综合征的基础和临床研究.临床肝胆病杂志,2020,36(11):2401-2405.
[11] Mandorfer M,Hecklng M. The renaissance of cholemic nephropathy: A likely underestimated cause of renal dysfunction in l iver disease.Hepatology,2019,69(5):1858-1860.
[12] 史慧敏,李瑞,陈红,等.《2018年欧洲肝病学会失代偿期肝硬化患者的管理临床实践指南》摘译.临床肝胆病杂志,2018,34(8):1632-1638.
[13] 高方博,白朝辉,林苏,等.《2020年英国胃肠病学会与英国肝病学会指南:肝硬化腹水管理》摘译.临床肝胆病杂志,2021,37(2):302-303.
[14] 中华医学会肝病学分会.肝硬化肝性脑病诊疗指南.临床肝胆病杂志,2018,34(10):2076-2089.
[15] 刘建军,刘建国,刘常林,等.对《肝硬化肝性脑病诊疗指南》中一个问题的商榷.肝脏,2019,24(6):713-714.
[16] European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis.J Hepatol,2018,69(2):406-460.
[17] 中华医学会肝病学分会.肝硬化诊治指南.临床肝胆病杂志,2019,35(11):2408-2425.
[18] Patel YR, Kurgansky KE,Imran TF,et al. Prognostic Significance of Baseline Serum Sodium in Heart Failure With Preserved Ejection Fraction.J Am Heart Assoc,2018,7(12):e007529.
[19] 李郑红,董育玮,陆伦根.肝肾综合征发生的危险因素、诊断和最新分型.临床肝胆病杂志,2020,36(11):2411-2414.
[20] Chawla LS,Bellomo R,Blhorac A,et al.Acute kidney disease and renal recovery: Consensus report of the Acute Disease Quality Initiative(ADQI) 16 Workgroup.2017,13(4):241-257.
[21] 中华医学会肝病学分会.肝硬化肝性脑病诊疗指南.临床肝胆病杂志,2018,34(10):2076-2089.
[22] Clchoz-Lach H,Mlchalak A. Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy.World J Gastroenterol,2013,19(1):26-34.
[23] Renato D,Michel N,Carmelina A,et al. Doea Accidental Overcorrection of Symptomatic Hyponatremia in Chronic Heart Failure Require Specific Therapeutic Adjustments for Preventing Central Pontine Myelinolysis？.J Cin Med Res,2017,9(4):266-272.
[24] Nagueh SF,Smlseth OA,Appleton CP,et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of echocardiography and the European Association of cardiovascular imaging.Eur Heart J Cardiovasc Imaging,2016,17(12):1321-1360.
[25] Adebayo D,Neong SF,Wong F. Refractory ascites in Liver cirrhosis.Am J Gastroenterol,2019,114(1):40-47.
[26] 中华医学会肝病学分会.肝硬化腹水及相关并发症的诊疗指南.临床肝胆病杂志,2017,33(10):1847-1863.
[27] Angeli P,Garclatsao G,Nadlm MK,et al. News in pathophysiology,definitionand classification of hepatorenal syndrome: A step beyond the INTERNATIONAL Club of Ascites(ICA) Consensus document.J Hepatol,2019,71(4):811-822.
[28] AmLn AA,Alabsawy EI,Jalan R,et al. Epidemiology,pathophysiology,and management of hepatorenal syndrome.Semin Nephrol,2019,39(1):17-30.
[29] 舒梦妮,李树臣.血清钠对肝硬化失代偿期患者并发症的影响.肝脏,2016,21(1):6-8.
[30] Alukal JJ,John S,Thuluvath PJ .Hyponatremia in cirrhosis: An update.Am J Gastroenterol,2020,115(11):1775-1785.
[31] Wong F,Watson H,Gerbes A,et al. Satavaptan for the management of ascites in cirrhosis: Efficacy and safety across the spectrum of ascites severity.Gut,2012,61(1):108-116.
[32] Martln P,Dlmartlnl A,Feng S,et al. Evaluation for Liver transplantation in adults: 2013 Practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation.Hepatology,2014,59(3):1144-1165.
[33] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation.J Hepatol,2016,64(2):433-485.
[34] 中华医学会器官移植学分会.中国肝移植受者选择与术前评估技术规范(2019版).临床肝胆病杂志,2020,36(1):40-43.
[35] Utako P,Emyoo T,Anothalslntawee T,et al. Clinical outcomes after liver transplantion for hepatorenal syndrome: A systematic review and meta analysis. Biomed Res Int,2018,2018:5362810.
[36] Kade G,Lubas A,Spalenlak S,et al. Application of the molecular adsorbent recirculating system in type l hepatorenal syndrome in the course of alcohol related acute on chronic liver failure.Med Sci Monit,2020,26:e923805.
[37] Facclorusso A. Hepatorenal syndrome type 1: Current challenges and future prospect.Ther Clin Risk Manag,2019,27(15):1383-1391.

终末期肝病周围循环功能障碍发生原因和机制与临床关系

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张舒茜, 赵红, 谢雯. 白蛋白在肝硬化患者中的应用现状[J]. 肝脏, 2022, 27(5): 511-513.
[2]	方青青, 陈颖, 陈炜, 简佑容, 李煜, 祝子华, 沈丹杰, 陈世耀, 李锋. 肝硬化伴食管胃静脉曲张患者内镜治疗后出血的危险因素分析[J]. 肝脏, 2022, 27(5): 526-530.
[3]	李琪, 曾阿娟, 丁惠国, 李磊. Wilson′s病相关肝硬化患者胆囊壁增厚影响因素分析[J]. 肝脏, 2022, 27(5): 531-535.
[4]	刘文艳, 马世河, 黄贵, 陈冲, 郑义彬. 恩替卡韦治疗的乙型肝炎肝硬化患者血清TIMP-1、MMP-2和GP73水平变化[J]. 肝脏, 2022, 27(5): 536-539.
[5]	冯丹妮, 张达利, 贺希, 张利娟, 周双男, 高银杰, 刘鸿凌. 酒精性肝硬化的肝移植受者血小板减少的病例对照研究[J]. 肝脏, 2022, 27(5): 540-542.
[6]	徐强, 方玮, 孙高亚, 吴炎. 肝硬化心肌病诊断与治疗的研究进展[J]. 肝脏, 2022, 27(4): 391-394.
[7]	王园园, 黄罡. 肝硬化肝癌术后发生肝衰竭的预测模型研究进展[J]. 肝脏, 2022, 27(4): 395-397.
[8]	魏望江, 韩晓涛, 白璐. 乙型肝炎肝硬化患者心脏病变的研究[J]. 肝脏, 2022, 27(4): 437-439.
[9]	陈丽芬, 姚朝光, 蓝婧, 黄理, 覃冬林, 欧琴, 吴晓云, 黄霜湘. MR弹性成像与超声内镜用于肝硬化食管胃底静脉曲张诊断的比较[J]. 肝脏, 2022, 27(4): 447-450.
[10]	车莹, 黄晓铨, 陈世耀. 用循证观点看待肝硬化门静脉血栓诊治中的争议[J]. 肝脏, 2022, 27(3): 261-263.
[11]	徐强, 方玮, 孙高亚, 吴炎. 肝硬化心肌病诊断与治疗研究进展[J]. 肝脏, 2022, 27(3): 267-270.
[12]	李锦秀, 沈镇扬, 蔡晓波, 陆伦根. 慢性肝病肝纤维化人群早期筛查的临床研究进展[J]. 肝脏, 2022, 27(3): 271-272.
[13]	任海霞, 闫华楠, 牛淑利, 郭永泽, 李博, 张宏伟, 安凯. 肝硬化患者口腔和肠道菌群的变化及其相关性[J]. 肝脏, 2022, 27(3): 330-333.
[14]	张丽丽, 胡建华, 靳华, 徐辉. 终末期原发性胆汁性肝硬化23例临床特点分析[J]. 肝脏, 2022, 27(3): 337-340.
[15]	刘宁, 周莹群. 胆汁酸对肝硬化疾病进展及治疗的意义[J]. 肝脏, 2022, 27(3): 376-379.